Literature DB >> 7815359

Characterization of the cloned human mu opioid receptor.

K Raynor1, H Kong, A Mestek, L S Bye, M Tian, J Liu, L Yu, T Reisine.   

Abstract

Opioid drugs exert a wide spectrum of physiological and behavioral effects, including effects on pain perception, mood, motor control and autonomic functions. The effects of opioids are mediated via a family of membrane-bound receptors, of which the most extensively characterized are the mu, delta and kappa receptors. We have now cloned the human homolog of the mu opioid receptor and, in the present study, we have examined its pharmacological profile. The human mu receptor has high affinities for several alkaloids of high abuse potential as well as a variety of peptide and nonpeptide drugs characterized previously as mu-selective, but not delta- or kappa-selective. Most importantly, the human mu receptor has higher affinity for morphine and methadone than does the rat mu receptor, despite the fact that these receptors are 95% identical at the amino acid level. The labeling of the receptor by agonist was decreased by nonhydrolyzable GTP analogs and by pertussis toxin treatment of cells expressing the human mu receptor, consistent with the coupling of the receptor to guanine nucleotide binding proteins. The human mu receptor functionally couples to the inhibition of adenylyl cyclase in a stereospecific and naloxone-reversible manner. We have also investigated the distribution of mRNAs encoding the mu receptor in human brain by Northern analysis, which demonstrates the existence of multiple transcripts of 13.5, 11, 4.3 and 2.8 kb, which were highly expressed in the hypothalamus, thalamus and subthalamic nucleus, more moderately expressed in the amygdala and caudate nucleus and which demonstrated lowest levels of expression in the hippocampus, substantia nigra and corpus callosum.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815359

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Characterization of the antinociceptive effects of the individual isomers of methadone after acute and chronic administrations.

Authors:  Richard W Morgan; Katherine L Nicholson
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

3.  Laminar distribution of the multiple opioid receptors in the human cerebral cortex.

Authors:  J M Hiller; L Q Fan
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.

Authors:  Ning-Sheng Cai; César Quiroz; Jordi Bonaventura; Alessandro Bonifazi; Thomas O Cole; Julia Purks; Amy S Billing; Ebonie Massey; Michael Wagner; Eric D Wish; Xavier Guitart; William Rea; Sherry Lam; Estefanía Moreno; Verònica Casadó-Anguera; Aaron D Greenblatt; Arthur E Jacobson; Kenner C Rice; Vicent Casadó; Amy H Newman; John W Winkelman; Michael Michaelides; Eric Weintraub; Nora D Volkow; Annabelle M Belcher; Sergi Ferré
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

5.  Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy.

Authors:  Matthew L Banks; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2010-07-30       Impact factor: 4.030

6.  (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist.

Authors:  C Thomsen; R Hohlweg
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

7.  Presynaptic modulation of synaptic transmission by opioid receptor in rat subthalamic nucleus in vitro.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  J Physiol       Date:  2002-05-15       Impact factor: 5.182

8.  Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.

Authors:  J J Ballesta; J Cremades; M Rodríguez-Muñoz; J Garzón; C C Faura
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

9.  Caged naloxone reveals opioid signaling deactivation kinetics.

Authors:  Matthew R Banghart; John T Williams; Ruchir C Shah; Luke D Lavis; Bernardo L Sabatini
Journal:  Mol Pharmacol       Date:  2013-08-19       Impact factor: 4.436

10.  A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.

Authors:  Chris M Brasel; Gregory W Sawyer; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2008-10-09       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.